Citations (29)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Jermaine D. Jones, Adam Bisaga, Verena E. Metz, Jeanne M. Manubay, Shanthi Mogali, Roberto Ciccocioppo, Gabriela Madera, Molly Doernberg & Sandra D. Comer. (2018) The PPARγ Agonist Pioglitazone Fails to Alter the Abuse Potential of Heroin, But Does Reduce Heroin Craving and Anxiety. Journal of Psychoactive Drugs 50:5, pages 390-401.
Read now
Read now
Thomas Forst, Markolf Hanefeld & Andreas Pfützner. (2011) Review of approved pioglitazone combinations for type 2 diabetes. Expert Opinion on Pharmacotherapy 12:10, pages 1571-1584.
Read now
Read now
Eiji Kutoh. (2010) Differential Effects of Pioglitazone on Metabolic Parameters in Newly Diagnosed, Drug-Naïve Japanese Patients with Type 2 Diabetes with or Without Metabolic Syndrome. Endocrine Research 35:3, pages 118-127.
Read now
Read now
Kohei Kaku, Hiroyuki Daida, Atsunori Kashiwagi, Akira Yamashina, Tsutomu Yamazaki, Shin-ichi Momomura, Takashi Iwase, Yoshimitsu Yamasaki, Kazuyuki Nagatsuka, Kazuo Kitagawa & Ryuzo Kawamori. (2009) Long-term effects of pioglitazone in Japanese patients with type 2 diabetes without a recent history of macrovascular morbidity. Current Medical Research and Opinion 25:12, pages 2925-2932.
Read now
Read now
Kohei Kaku. (2009) Efficacy and safety of therapy with metformin plus pioglitazone in the treatment of patients with type 2 diabetes: a double-blind, placebo-controlled, clinical trial. Current Medical Research and Opinion 25:5, pages 1111-1119.
Read now
Read now
Shu-Feng Zhou, Jun-Ping Liu & Balram Chowbay. (2009) Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metabolism Reviews 41:2, pages 89-295.
Read now
Read now
Mario Cazzola, Chiara Ciaprini, Clive P Page & Maria G Matera. (2007) Targeting systemic inflammation: novel therapies for the treatment of chronic obstructive pulmonary disease. Expert Opinion on Therapeutic Targets 11:10, pages 1273-1286.
Read now
Read now
Andreas Pfützner, Matthias M Weber & Thomas Forst. (2007) Pioglitazone: update on an oral antidiabetic drug with antiatherosclerotic effects. Expert Opinion on Pharmacotherapy 8:12, pages 1985-1998.
Read now
Read now
Articles from other publishers (21)
Faisal M. Aqlan, Abdullah S. Al-Bogami, Norah F. Alqahtani, Mohmmad Younus Wani & Salman A. Khan. (2022) Thiazolidinone: A structural motif of great synthetic and biological importance. Journal of Molecular Structure 1250, pages 131771.
Crossref
Crossref
Dan Wang, Sirong He, Bicui Liu & Chuntao Liu. (2018) MiR-27-3p regulates TLR2/4-dependent mouse alveolar macrophage activation by targetting PPARγ. Clinical Science 132:9, pages 943-958.
Crossref
Crossref
Hidenori Hirukawa, Mitsuru Hashiramoto, Yukio Tanizawa & Kohei Kaku. (2018) Remission of hyperglycemia after withdrawal of oral antidiabetic drugs in Japanese patients with early-stage type 2 diabetes. Journal of Diabetes Investigation.
Crossref
Crossref
Wen Wang, Xu Zhou, Joey S. W. Kwong, Ling Li, Youping Li & Xin Sun. (2017) Efficacy and safety of thiazolidinediones in diabetes patients with renal impairment: a systematic review and meta-analysis. Scientific Reports 7:1.
Crossref
Crossref
Andreas Pfützner. (2014) A New Metabolite Panel Test for Identification of Patients With Impaired Glucose Tolerance? Analysis of the Article by Cobb et al. Journal of Diabetes Science and Technology 9:1, pages 77-79.
Crossref
Crossref
Yan Yin, Gang Hou, Erran Li, Qiuyue Wang & Jian Kang. (2014) PPAR Gamma agonists regulate tobacco smoke-induced toll like receptor 4 expression in alveolar macrophages. Respiratory Research 15:1.
Crossref
Crossref
Robert C. Smith, Hua Jin, Chunbo Li, Nigel Bark, Anantha Shekhar, Sauburah Dwivedi, Catherine Mortiere, James Lohr, Qiaoyan Hu & John M. Davis. (2013) Effects of pioglitazone on metabolic abnormalities, psychopathology, and cognitive function in schizophrenic patients treated with antipsychotic medication: A randomized double-blind study. Schizophrenia Research 143:1, pages 18-24.
Crossref
Crossref
André J. Scheen. (2012) Outcomes and lessons from the PROactive study. Diabetes Research and Clinical Practice 98:2, pages 175-186.
Crossref
Crossref
Shinzo Hiroi, Kumi Matsuno, Masashi Hirayama, Takaki Hayakawa, Norihito Yoshioka & Koji Kawakami. (2012) Evaluation of the bioequivalence of a fixed-dose combination tablet of pioglitazone–metformin versus commercial tablets in healthy Japanese male volunteers. Diabetes Management 2:5s, pages 13-20.
Crossref
Crossref
Shinzo Hiroi, Kumi Matsuno, Masashi Hirayama, Takaki Hayakawa, Norihito Yoshioka & Koji Kawakami. (2012) Bioequivalence evaluation of pioglitazone orally disintegrating tablet formulation. Diabetes Management 2:5s, pages 3-11.
Crossref
Crossref
Giuseppe Derosa. (2010) Efficacy and Tolerability of Pioglitazone in Patients with Type 2 Diabetes Mellitus. Drugs 70:15, pages 1945-1961.
Crossref
Crossref
Petra B. Musholt, Thomas Schöndorf, Andreas Pfützner, Cloth Hohberg, Iris Kleine, Winfried Fuchs, Silvia Hehenwarter, Gerhard Dikta, Benedikt Kerschgens & Thomas Forst. (2009) Combined Pioglitazone and Metformin Treatment Maintains the Beneficial Effect of Short-Term Insulin Infusion in Patients with Type 2 Diabetes: Results from a Pilot Study. Journal of Diabetes Science and Technology 3:6, pages 1442-1450.
Crossref
Crossref
Gualberto Rua?o, James Bernene, Andreas Windemuth, Bruce Bower, Detlef Wencker, Richard L. Seip, Mohan Kocherla, Theodore R. Holford, William A. Petit & Steven Hanks. (2009) Physiogenomic comparison of edema and BMI in patients receiving rosiglitazone or pioglitazone. Clinica Chimica Acta 400:1-2, pages 48-55.
Crossref
Crossref
Yusuke Moritoh, Koji Takeuchi, Tomoko Asakawa, Osamu Kataoka & Hiroyuki Odaka. (2009) The dipeptidyl peptidase-4 inhibitor alogliptin in combination with pioglitazone improves glycemic control, lipid profiles, and increases pancreatic insulin content in ob/ob mice. European Journal of Pharmacology 602:2-3, pages 448-454.
Crossref
Crossref
T. Forst, E. Karagiannis, G. Lübben, C. Hohberg, T. Schöndorf, G. Dikta, M. Drexler, M. Morcos, W. Dänschel, M. Borchert & A. Pfützner. (2008) Pleiotrophic and anti-inflammatory effects of pioglitazone precede the metabolic activity in type 2 diabetic patients with coronary artery disease. Atherosclerosis 197:1, pages 311-317.
Crossref
Crossref
Ming Zhang, Sheng-hua Zhou, Sp Zhao, Xu-ping Li, Li-Ping Liu & Xiang-Qian Shen. (2008) Pioglitazone Can Downregulate Bone Morphogenetic Protein-2 Expression Induced by High Glucose in Human Umbilical Vein Endothelial Cells. Pharmacology 81:4, pages 312-316.
Crossref
Crossref
Guido Eibl. (2008)
The Role of PPAR-
and Its Interaction with COX-2 in Pancreatic Cancer
. PPAR Research 2008, pages 1-6.
Crossref
Crossref
Philip Raskin. (2008) Why insulin sensitizers but not secretagogues should be retained when initiating insulin in type 2 diabetes. Diabetes/Metabolism Research and Reviews 24:1, pages 3-13.
Crossref
Crossref
Mario Cazzola, Maria Gabriella Matera, Paola Rogliani & Clive Page. (2007) Treating systemic effects of COPD. Trends in Pharmacological Sciences 28:10, pages 544-550.
Crossref
Crossref
Irene Katzan. (2007) Can add-on pioglitazone prevent recurrent stroke in patients with type 2 diabetes?. Nature Clinical Practice Neurology 3:9, pages 486-487.
Crossref
Crossref
A. Pfützner & T. Forst. (2007) A Diabetes Outcome and Progression Trial – Die ADOPT StudieA Diabetes Outcome Progression Trial – the ADOPT Study. Der Diabetologe 3:4, pages 261-269.
Crossref
Crossref